This clinical trial aims to evaluate the safety and effectiveness of a new vaccine called MenPenta for preventing meningococcal disease. This vaccine targets five different types of meningococcal bacteria (groups A, B, C, W, and Y) that can cause serious infections of the brain and spinal cord lining. The study will compare the new vaccine with currently approved meningococcal vaccines.
The research involves three different age groups: children aged 2 to 9 years, toddlers aged 12 to 15 months, and infants aged 2 months. Some participants will receive the new MenPenta vaccine alone, while others will receive it along with standard childhood vaccines. The study will monitor how well the immune system responds to the vaccine and track any side effects that may occur.
During the study, participants will receive multiple doses of vaccines through intramuscular injection. Blood samples will be taken to measure the body’s immune response to the vaccines. The researchers will carefully monitor all participants for immediate reactions after vaccination and continue to track their health throughout the study period. Other routine vaccines that may be given during the study include Prevenar 13 (for protection against pneumococcal disease), Hexyon (a combination vaccine that protects against six different diseases), and RotaTeq (for protection against rotavirus).
Czechia 
Denmark 
Finland 
Germany 
Poland 
Spain 
